LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Serological Biomarker Aids Diagnosis of Rare Kidney Disease Without Biopsy

By LabMedica International staff writers
Posted on 15 Jun 2022
Print article
Image: Detection of autoantibodies against PLA2R and THSD7A (Photo courtesy of EUROIMMUN)
Image: Detection of autoantibodies against PLA2R and THSD7A (Photo courtesy of EUROIMMUN)

Primary membranous nephropathy (pMN) is a chronic inflammatory kidney disease that can lead to kidney failure. Antibodies against PLA2R (phospholipase A2 receptors) occur with a prevalence of 70 to 80% and a specificity of over 99%. Anti-PLA2R have been recognized as a significant serological biomarker for the diagnosis of pMN in the new guideline from the KDIGO (Kidney Disease: Improving Global Outcomes). Diagnosis of pMN can now be made without biopsy if the serological marker anti-PLA2R is present alongside the clinical symptoms.

Antibodies in pMN can be determined using exclusive test systems from EUROIMMUN (Luebeck, Germany), a PerkinElmer, Inc. (Waltham, MA; USA) company. As well as aiding diagnosis, measurement of anti-PLA2R is also used to assess the activity and progression of pMN. Phases of clinical remission and relapses are typically preceded by a respective change in the antibody titer. The antibody concentration is one of the criteria used to assess the risk of progression to renal failure. Anti-PLA2R determination is suitable for assessing responses to immunosuppressive therapy. According to the guideline, the antibody concentration should be measured three or six months after the start of therapy. The determined value serves as a basis for maintaining or adjusting the current treatment.

The predictive value of anti-PLA2R antibodies is also relevant for assessing pMN patients undergoing kidney transplantation. High antibody titers before a transplant indicate a high risk of relapse. After transplantation, regular determination of the antibody level helps to predict possible relapses early, allowing prompt intervention. In addition to anti-PLA2R, autoantibodies against thrombospondin type 1 domain-containing 7A (THSD7A) also occur in pMN at a prevalence of 2 to 5% and a high specificity. As they primarily occur in anti-PLA2R-negative pMN patients, they play a complementary role in pMN serodiagnostics.

EUROIMMUN’s indirect immunofluorescence test (IIFT) enables qualitative to semi-quantitative detection of anti-PLA2R or anti-THSD7A antibodies using transfected cells expressing the corresponding antigen on their surface. Anti-PLA2R antibodies can be measured quantitatively using ELISA or chemiluminescence immunoassay (ChLIA) based on recombinant receptor. The quantitative measurement is highly suited to disease and therapy monitoring and can be performed efficiently at high throughput. The IIFT, ELISA and ChLIA procedures are all automatable.

Related Links:
EUROIMMUN 
PerkinElmer, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more